$ABBV was trading lower on friday after the the FDA pushed back the review period for the company's supplemental marketing application for upadacitinib in active psoriatic arthritis. Despite the big drop, it fell right to key support (right at the bottom of a range) making a good entry here in terms of RR, having a tight stop and aiming for the top of range (gap fill). For options, look for leaps.
交易开始:
Added a swing position at open, looks great so far.
交易结束：到达目标:
trimmed most of my position here and only have runner left. great profits!
Autopsy of my trades.
Admin of SimbaStocks.
Not a registered financial advisor, all related content are my opinions and solely my opinions.
Admin of SimbaStocks.
Not a registered financial advisor, all related content are my opinions and solely my opinions.